Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-270

Well if it isn't results that remind you that we are investing in the clinical research space I don't know what will. One thing that I read yesterday was a quote from GW pharma CEO. I thought it a poignant point to keep in mind when reading results.

"Even though some clinical trials went badly, and it took more than a decade for the first cannabis drug to reach the UK market, this is quite normal for new medicines, he says and the GW team never lost faith in the treatment's potential."I don't think we ever doubted the efficacy because the data we were seeing were very consistent from the early days," says Gover. "There have been, without doubt, difficult times for GW, but it is hard to recall a drug development programme that hasn't had delays and setbacks in its history."

Sounds like we have a world-leading potential product that has comparable lesion reduction counts, and a would class safety profile. We have some questions to investigate with our phase 2 results, and will feed into further investigations. Is it just as simple in a different supplier? It's nice for the board not to sugar coat it. And with a general meeting just around the corner maybe they are prepared with the direction ahead. Who knows maybe it's as simple as on into phase 3, and see what changes if any the FDA want us to implement. Some positive paths forward with some money to do it. Lets see.